Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Treating Infectious Diseases in a Microbial World: Report of Two Workshops on Novel Antimicrobial Therapeutics.

National Research Council (US) Committee on New Directions in the Study of Antimicrobial Therapeutics: New Classes of Antimicrobials, National Research Council (US) Committee on New Directions in the Study of Antimicrobial Therapeutics: Immunomodulation.

Washington (DC): National Academies Press (US); 2006.

2.

Antimicrobial resistance: it's not just for hospitals.

Bancroft EA.

JAMA. 2007 Oct 17;298(15):1803-4. No abstract available.

PMID:
17940239
3.

Invasive methicillin-resistant Staphylococcus aureus infections in the United States.

Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK; Active Bacterial Core surveillance (ABCs) MRSA Investigators..

JAMA. 2007 Oct 17;298(15):1763-71.

PMID:
17940231
4.

Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases.

Guo RT, Cao R, Liang PH, Ko TP, Chang TH, Hudock MP, Jeng WY, Chen CK, Zhang Y, Song Y, Kuo CJ, Yin F, Oldfield E, Wang AH.

Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10022-7. Epub 2007 May 29.

5.

Staphyloxanthin plays a role in the fitness of Staphylococcus aureus and its ability to cope with oxidative stress.

Clauditz A, Resch A, Wieland KP, Peschel A, Götz F.

Infect Immun. 2006 Aug;74(8):4950-3.

6.

Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity.

Liu GY, Essex A, Buchanan JT, Datta V, Hoffman HM, Bastian JF, Fierer J, Nizet V.

J Exp Med. 2005 Jul 18;202(2):209-15. Epub 2005 Jul 11.

7.

Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.

Nishimoto T, Amano Y, Tozawa R, Ishikawa E, Imura Y, Yukimasa H, Sugiyama Y.

Br J Pharmacol. 2003 Jul;139(5):911-8.

8.

Syntheses and biological evaluation of novel quinuclidine derivatives as squalene synthase inhibitors.

Ishihara T, Kakuta H, Moritani H, Ugawa T, Sakamoto S, Tsukamoto S, Yanagisawa I.

Bioorg Med Chem. 2003 May 29;11(11):2403-14.

PMID:
12735986
9.

Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers.

Sharma A, Slugg PH, Hammett JL, Jusko WJ.

J Clin Pharmacol. 1998 Dec;38(12):1116-21.

PMID:
11301563
10.

Bacterial virulence as a target for antimicrobial chemotherapy.

Alksne LE, Projan SJ.

Curr Opin Biotechnol. 2000 Dec;11(6):625-36. Review. Erratum in: Curr Opin Biotechnol 2001 Feb;12(1):112.

PMID:
11102800
12.

Crystal structure of human squalene synthase. A key enzyme in cholesterol biosynthesis.

Pandit J, Danley DE, Schulte GK, Mazzalupo S, Pauly TA, Hayward CM, Hamanaka ES, Thompson JF, Harwood HJ Jr.

J Biol Chem. 2000 Sep 29;275(39):30610-7.

13.
14.
15.

Estimation of oral bioavailability of a long half-life drug in healthy subjects.

Sharma A, Slugg PH, Hammett JL, Jusko WJ.

Pharm Res. 1998 Nov;15(11):1782-6.

PMID:
9834003
16.

alpha-Phosphonosulfonic acids: potent and selective inhibitors of squalene synthase.

Magnin DR, Biller SA, Chen Y, Dickson JK Jr, Fryszman OM, Lawrence RM, Logan JV, Sieber-McMaster ES, Sulsky RB, Traeger SC, Hsieh DC, Lan SJ, Rinehart JK, Harrity TW, Jolibois KG, Kunselman LK, Rich LC, Slusarchyk DA, Ciosek CP Jr.

J Med Chem. 1996 Feb 2;39(3):657-60. No abstract available.

PMID:
8576905

Supplemental Content

Support Center